Requirements for acquiring a high-quality house dust mite extract for allergen immunotherapy

Drug Design, Development and Therapy

Volumn 6, Issue , 2012, Pages 117-123

  Frati, Franco ^a   Incorvaia, Cristoforo ^b   David, Marie ^c   Scurati, Silvia ^c   Seta, Simona ^d   Padua, Guglielmo ^d   Cattaneo, Eleonora ^a   Cavaliere, Carlo ^e   Rienzo, Alessia Di ^f   Dell'Albani, Ilaria ^a   Puccinelli, Paola ^a  

^a Medical and Scientific and Regulatory Department   (Italy)

^b ICP Hospital   (Italy)

^c Stallergenes SA   (France)

^d Medical Marketing Department   (Italy)

^e SAPIENZA UNIVERSITY OF ROME   (Italy)

^f Azienda Sanitaria Locale (ASL)   (Italy)

Author keywords

Allergen extracts; Asthma; House dust mite; Rhinitis; Sublingual immunotherapy

Indexed keywords

HOUSE DUST ALLERGEN; PLACEBO; STALORAL 300; UNCLASSIFIED DRUG;

ALLERGEN IMMUNOTHERAPY; ALLERGIC ASTHMA; ALLERGIC RHINITIS; ANAPHYLAXIS; BURNING SENSATION; COST EFFECTIVENESS ANALYSIS; DRUG COST; DRUG EFFICACY; DRUG MECHANISM; DRUG SAFETY; DRUG TOLERABILITY; DRUG WITHDRAWAL; DYSPNEA; GASTROINTESTINAL SYMPTOM; HUMAN; HYPOTENSION; IMMUNOTHERAPY; INJECTION SITE REACTION; MOUTH DISEASE; NONHUMAN; PRURITUS; RESPIRATORY TRACT ALLERGY; REVIEW; STANDARDIZATION; SUBCUTANEOUS IMMUNOTHERAPY; SUBLINGUAL IMMUNOTHERAPY; URTICARIA; ANIMAL; ARTICLE; ASTHMA; COST BENEFIT ANALYSIS; DESENSITIZATION; ECONOMICS; HAY FEVER; IMMUNOLOGY; PERENNIAL RHINITIS; PYROGLYPHIDAE; STANDARD;

ANIMALS; ASTHMA; COST-BENEFIT ANALYSIS; DESENSITIZATION, IMMUNOLOGIC; HUMANS; PYROGLYPHIDAE; RHINITIS, ALLERGIC, PERENNIAL; RHINITIS, ALLERGIC, SEASONAL;

EID: 84865312393     PISSN: 11778881     EISSN: None     Source Type: Journal    
DOI: 10.2147/DDDT.S30908     Document Type: Review

References (63)

1. Platts-Mills TAE, De Weck AL. Dust mite allergens and asthma - a worldwide problem. J Allergy Clin Immunol. 1989;83:416-427.
2. Arlian LG, Morgan MS, Neal JS. Dust mite allergens: ecology and distribution. Curr Allergy Asthma Rep. 2002;2:401-411.
3. Zock J P, Heinrich J, Jarvis D, et al. Distribution and determinants of house dust mite allergens in Europe: the European Community Respiratory Health Survey II. J Allergy Clin Immunol. 2006;118: 682-690.
4. Colloff MJ. Taxonomy and identifcation of dust mites. Allergy. 1998; 53 Suppl 48:7-12.
5. Thomas WR, Hales BJ, Smith WA. House dust mite allergens in asthma and allergy. Trends Mol Med. 2010;16:321-328.
6. O'Neil SE, Heinrich TK, Hales BJ, et al. The chitinase allergens Der p 15 and Der p 18 from Dermatophagoides pteronyssinus. Clin Exp Allergy. 2006;36:831-839.
7. Thomas WR, Heinrich TK, Smith WA, Hales BJ. Pyroglyphid house dust mite allergens. Protein Pept Lett. 2007;14:943-953.
8. Park GM, Lee SM, Lee I Y, et al. Localization of a major allergen, Der p 2, in the gut and faecal pellets of Dermatophagoides pteronyssinus. Clin Exp Allergy. 2000;30:1293-1297.
9. Pittner G, Vrtala S, Thomas WR, et al. Component-resolved diagnosis of house dust mite allergy with purifed natural and recombinant mite allergens. Clin Exp Allergy. 2004;34:597-603.
10. Reese G, Ayuso R, Lehrer SB. Tropomyosin: an invertebrate pan-allergen. Int Arch Allergy Immunol. 1999;119:247-258.
11. Hales BJ, Martin AC, Pearce LJ, et al. IgE and IgG anti-house dust mite specifcities in allergic disease. J Allergy Clin Immunol. 2006;118:361-367.
12. Kidon MI, Chin C W, Kang LW, et al. Mite component-specifc IgE repertoire and phenotypes of allergic disease in childhood: the tropical perspective. Pediatr Allergy Immunol. 2011;22:202-210.
13. Karp CL. Guilt by intimate association: what makes an allergen an allergen? J Allergy Clin Immunol. 2010;125:955-960.
14. Jacquet A. The role of house dust mites-induced innate immunity in development of allergic response. Int Arch Allergy Immunol. 2011;155:95-105.
15. Bessot JC, Pauli G. Mite allergens: an overview. Eur Ann Allergy Clin Immunol. 2011;43:141-156.
16. Jacquet A. The role of innate immunity activation in house dust mite allergy. Trends Mol Med. 2011;17:604-611.
17. Novak N, Koch S, Allam J P, Bieber T. Dendritic cells: bridging innate and adaptive immunity in atopic dermatitis. J Allergy Clin Immunol. 2010;125:50-59.
18. Inal A, Kendirli SG, Yilmaz M, et al. Indices of lower airway infammation in children monosensitized to house dust mite after nasal allergen challenge. Allergy. 2008;63:1345-1351.
19. Incorvaia C, Frati F, Verna N, D'Alò S, Motolese A, Pucci S. Allergy and the skin. Clin Exp Immunol. 2008;153 Suppl 1:27-29.
20. Leung DYM. Our evolving understanding of the functional role of filaggrin in atopic dermatitis. J Allergy Clin Immunol. 2009;124: 494-495.
21. Guilbert T W, Morgan WJ, Zeiger RS, et al. Long-term inhaled corticosteroids in preschool children at high risk of asthma. N Engl J Med. 2006;354:1985-1997.
22. Simpson A, Custovic A. The role of allergen avoidance in the secondary prevention of atopic disorders. Curr Opin Allergy Clin Immunol. 2005;5:223-227.
23. Incorvaia C, Frati F. One century of allergen-specifc immunotherapy for respiratory allergy. Immunotherapy. 2011;3:629-635.
24. Dreborg S. Mite allergens: collection, determination, expression of results and risk levels for sensitization and symptoms induction. Allergy. 1998;53 Suppl 48:88-91.
25. Batard T, Hrabina A, Bi XZ, et al. Production and proteomic characterization of pharmaceutical-grade Dermatophagoides pteronyssinus and Dermatophagoides farinae extracts for allergy vaccines. Int Arch Allergy Immunol. 2006;140:295-305.
26. van Ree R. Indoor allergens: relevance of major allergen measurements and standardization. J Allergy Clin Immunol. 2007;119:270-277.
27. Fiocchi A, Pajno G, La Grutta S, et al. Safety of SLIT in children aged 3 to 7 years. Ann Allergy Asthma Immunol. 2005;95:254-258.
28. Rossi R, Monasterolo RE. A pilot study of feasibility of ultra-rush (20-25 minutes) sublingual-swallow immunotherapy in 679 patients (699 sessions) with allergic rhinitis and/or asthma. Int J Immunopathol Pharmacol. 2005;18:277-285.
29. Tripodi S, Di Rienzo Businco A, Benincori N, et al. Safety and tolerability of ultra-rush induction, less than one hour, of sublingual immunotherapy in children. Int Arch Allergy Immunol. 2005;139:149-152.
30. Ferres J, Justicia JR, Garcia M P, et al. Effcacy of high-dose sublingual immunotherapy in children allergic to house dust mites in real-life clinical practice. Allergol Immunopathol (Madr). 2011;39:122-127.
31. Gidaro GB, Marcucci F, Sensi L, et al. The safety of sublingual-swallow immunotherapy: an analysis of published studies. Clin Exp Allergy. 2005;35:565-571.
32. Cadario G, Ciprandi G, Di Cara G, et al. Comparison between continuous or intermittent schedules of sublingual immunotherapy for house dust mites: effects on compliance, patient's safsfaction, quality of life, and safety. Int J Immunopathol Pharmacol. 2008;21:471-473.
33. Canonica G W, Bousquet J, Casale T, et al. Sublingual immunotherapy: World Allergy Organization Position Paper 2009. Allergy. 2009; 64 Suppl 91:1-59.
34. Jorgensen AW, Hilden J, Gotzsche PC. Cochrane reviews compared with industry supported meta-analyses and other meta-analyses of the same drugs: systematic review. Br Med J. 2006;333:782.
35. Compalati E, Passalacqua G, Bonini M, Canonica G W. The effcacy of sublingual immunotherapy for house dust mites respiratory allergy: results of a GA2LEN meta-analysis. Allergy. 2009;64:1570-1579.
36. Bousquet J, Scheinmann P, Guinnepain MT, et al. Sublingual swallow immunotherapy (SLIT) in patients with asthma due to house dust mites: a double-blind placebo-controlled study. Allergy. 1999;54:249-260.
37. Guez S, Vatrinet C, Fadel R, Andrè C. House dust mite sublingual swallow immunotherapy in perennial rhinitis: a double-blind placebocontrolled study. Allergy. 2000;55:369-375.
38. Bahcecilier NN, Isik U, Barlan IB, Basaran N. Effcacy of sublingual immunotherapy in children with asthma and rhinitis: a double-blind, placebo-controlled trial. Pediatr Pulmonol. 2001;32:49-55.
39. Niu CK, Chen W Y, Huang JL, et al. Efficacy of sublingual immunotherapy with high-dose mite extracts in asthma: a multi-center, double-blind, randomized, and placebo-controlled study in Taiwan. Respir Med. 2006;100:1374-1383.
40. Lue KH, Lin YH, Sun HL, et al. Clinical and immunological effect of sublingual immunotherapy in asthmatic children sensitized to mites:a double-blind, randomized, placebo-controlled study. Pediatr Allergy Immunol. 2006;17:408-415.
41. Pham-Ti N, Scheinmann P, Fadel R, et al. Assessment of sublingual immunotherapy effcacy in children with house dust mite-induced allergic asthma optimally controlled by pharmacologic treatment and mite-avoidance measures. Pediatr Allergy Immunol. 2007;18:47-57.
42. Mortemousque B, Bertel F, De Casamayor P, et al. House-dust mite sublingual-swallow immunotherapy in perennial conjunctivitis: a double-blind, placebo-controlled study. Clin Exp Allergy. 2003:33464-33469.
43. Nuhoglu Y, Ozumut SS, Ozdemir C, et al. Sublingual immunotherapy to house dust mites in pediatric patients with allergic rhinitis and asthma: a retrospective analysis of clinical course over a 3-year follow-up period. J Investig Allergol Clin Immunol. 2007;17:375-378.
44. Radulovic S, Wilson D, Calderon M, Durham S. Systematic reviews of sublingual immunotherapy (SLIT). Allergy. 2011;66:740-752.
45. Blazowski L. Anaphylactic shock because of sublingual immunotherapy overdose during third year of maintenance dose. Allergy. 2008;63:374.
46. Frati F, Sensi L, Di Rienzo V, et al. A model for management of sublingual immunotherapy. Eur Ann Allergy Clin Immunol. 2003;35:56-60.
47. Buchner K, Siepe M. Nutzen der Hyposensibilisierung unter wirtschaftlichen Aspekten. [Benefts of immunotherapy with economic aspects]. Allergo J. 1995;4:156-163. German.
48. Berto P, Frati F, Incorvaia C. Economic studies of immunotherapy: a review. Curr Opin Allergy Clin Immunol. 2008;8:585-589.
49. Ariano R, Berto P, Incorvaia C, et al. Economic evaluation of sublingual immunotherapy vs symptomatic treatment in allergic asthma. Ann Allergy Asthma Immunol. 2009;103:254-259.
50. Incorvaia C, Mauro M, Ridolo E, et al. Patient's compliance with allergen immunotherapy. Patient Prefer Adherence. 2008;2:247-261.
51. Noon L, Cantab BC, Eng FR. Prophylactic inoculation against hay fever. Lancet. 1911;177:1572-1573.
52. Frankland A, Augustin R. Prophylaxis of summer hay fever and asthma: a controlled trial comparing crude grass pollen extract with the isolated main protein components. Lancet. 1954;266:1055-1058.
53. Abramson MJ, Puy RM, Weiner JM. Is allergen immunotherapy effective in asthma? A meta-analysis of randomized controlled trials. Am J Respir Crit Care Med. 1995;151:969-974.
54. Calderon MA, Alves B, Jacobson M, et al. Allergen injection immunotherapy for seasonal allergic rhinitis. Cochrane Database Syst Rev. 2007;1: CD001936.
55. Radulovic S, Calderon MA, Wilson D, Durham S. Sublingual immunotherapy for allergic rhinitis. Cochrane Database Syst Rev. 2010;12:CD002893.
56. Abramson MJ, Puy RM, Weiner JM. Injection immunotherapy for asthma. Cochrane Database Syst Rev. 2010;8:CD001186.
57. Maggi E. T cell responses induced by allergen-specifc immunotherapy. Clin Exp Immunol. 2010;161:10-18.
58. Taylor A, Verhagen J, Blaser K, et al. Mechanisms of immune suppression by interleukin-10 and transforming growth factor beta: the role of T regulatory cells. Immunology. 2006;117:433-442.
59. Bohle B, Kinaciyan T, Gestrmayr M, et al. Sublingual immunotherapy induces IL-10-producing T regulatory cells, allergen-specifc T. cell tolerance, and immune deviation. J Allergy Clin Immunol. 2007;120:707-713.
60. Gaffn JM, Phipatanakul W. The role of indoor allergens in the development of asthma. Curr Opin Allergy Clin Immunol. 2009;9:128-135.
61. Committee on Safety in Medicine. CSM update: desensitizing vaccines. Br Med J. 1986;293:948.
62. Lockey RF, Benedikt LM, Turkeltaub PC, Bukantz SC. Fatalities from immunotherapy (IT) and skin testing (ST). J Allergy Clin Immunol. 1987;79:660-677.
63. Marcucci F, Sensi L, Di Cara G, et al. Dose dependence of immunological response to sublingual immunotherapy. Allergy. 2005;60:952-956.